P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial

Similar Items

• O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
  by: Laura Geraldino-Pardilla, et al.
  Published: (2024-03-01)
• P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
  by: Richard Furie, et al.
  Published: (2024-03-01)
• S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
  by: S Banerjee, et al.
  Published: (2022-10-01)
• LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
  by: Chun Wu, et al.
  Published: (2023-07-01)
• Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
  by: Arianna Zhang, BS, et al.
  Published: (2024-03-01)